Advances in the management of malignant hemopathies: The role of statins

Recent Patents on DNA and Gene Sequences

Volumn 7, Issue 1, 2013, Pages 57-61

  Mihǎilǎ, Romeo Gabriel ^a,b  

^a LUCIAN BLAGA UNIVERSITY OF SIBIU   (Romania)

^b Spitalul Clinic Judetean de Urgenta Cluj   (Romania)

Author keywords

Atorvastatin; Cytarabine; Dipyridamole; Gene expression profile; Geranyl geranylation; Idarubicine; Imatinib mesylate; Leukemia; Lymphoma; Myopathy; Pravastatin; Retinoids; Rituximab; Simvastatin; Statin; Thrombin

Indexed keywords

ATORVASTATIN; CD20 ANTIGEN; CYTARABINE; CYTOSTATIC AGENT; DIPYRIDAMOLE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IDARUBICIN; IMATINIB; INTERCELLULAR ADHESION MOLECULE 1; LATENT MEMBRANE PROTEIN 1; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN RECEPTOR; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MEVINOLIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PRAVASTATIN; REACTIVE OXYGEN METABOLITE; RETINOIC ACID; RITUXIMAB; SIMVASTATIN; TIPIFARNIB;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; AMINOTRANSFERASE BLOOD LEVEL; ANTICOAGULATION; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CHEMOSENSITIVITY; CHOLESTEROL SYNTHESIS; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; DNA DAMAGE; DRUG MEGADOSE; DRUG RELEASE; ENDOTHELIAL DYSFUNCTION; FAMILIAL HYPERCHOLESTEROLEMIA; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION PROFILING; GENE MUTATION; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; KIDNEY FAILURE; LIPID METABOLISM; LYMPHOMA; MEMBRANE PERMEABILITY; MOLECULAR BIOLOGY; MULTIPLE MYELOMA; MUSCLE ATROPHY; MYALGIA; MYOPATHY; MYOSITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIDE EFFECT; THROMBOPHILIA; TREATMENT RESPONSE; VASCULAR DISEASE;

GENE EXPRESSION REGULATION, NEOPLASTIC; HEMATOLOGIC NEOPLASMS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LEUKEMIA; LIPID METABOLISM; LYMPHOMA; MOLECULAR BIOLOGY; TREATMENT OUTCOME;

EID: 84875974881     PISSN: 18722156     EISSN: None     Source Type: Journal    
DOI: 10.2174/1872215611307010008     Document Type: Article

References (39)

1. Cvetkovic Z, Cvetkovic B, Petrovic M, et al. Lipid profile as a prognostic factor in cancer patients. J BUON 2009; 4: 501-6.
2. Pugliese L, Bernardini I, Pacifico N, et al. Severe hypocholesterolaemia is often neglected in haematological malignancies. Eur J Cancer 2010; 46:1735-43.
3. Fuchs D, Berges C, Opelz G, Daniel V, Naujokat C. HMG-CoA reductase inhibitor simvastatin overcomes bortezomib-induced apoptosis resistance by disrupting a geranylgeranyl pyrophosphatedependent survival pathway. Biochem Biophys Res Commun 2008; 374: 309-14.
4. Nonaka M, Uota S, Saitoh Y, et al. Role for protein geranylgeranylation in adult T-cell leukemia cell survival. Exp Cell Res 2009; 315, 141-50.
5. Sassano A, Katsoulidis E, Antico G, et al. Suppressive effects of statins on acute promyelocytic leukemia cells. Cancer Res 2007; 67: 4524-32.
6. Winiarska M, Bil J, Wilczek E, et al. Statins impair antitumor effects of rituximab by inducing conformational changes of CD20. PLoS Med 2008; 5: Pp.e64.
7. Mihǎilǎ RG. In: Kelishadi R, Eds. Dyslipidemia - From Prevention to Treatment. Rijeka: InTech Publishing House 2012: pp. 391-410. Available at: http://www.intechopen.com/books/dyslipidemiafrom- prevention-to-treatment/cholesterol-and-triglyceridesmetabolism- disorder-in-malignant-hemopathies. (Accessed on: April 23, 2012).
8. Goard CA, Mather RG, Vinepal B, et al. Differential interactions between statins and P-glycoprotein: implications for exploiting statins as anticancer agents. Int J Cancer 2010; 127: 2936-48.
9. Cohen H, Bielorai B, Harats D, Toren A, Pinhas-Hamiel O. Conservative treatment of L-asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2010; 54: 703-6.
10. Trimis G, Moschovi M, Papassotiriou I, Chrousos G, Tzortzatou- Stathopoulou F. Early indicators of dysmetabolic syndrome in young survivors of acute lymphoblastic leukemia in childhood as a target for preventing disease. J Pediatr Hematol Oncol 2007; 29: 309-14.
11. Baker JB, Shak S, Gianni L. Gene expression markers for predicting response to chemotherapy. US7871769, 2011.
12. Radich JP, Dai H, Mao M, Schelter JM, Linsley PS. Genes associated with progression and response in chronic myeloid leukemia and uses thereof. US8014957, 2011.
13. Janikova A, Tichy B, Supikova J, et al. Gene expression profiling in follicular lymphoma and its implication for clinical practice. Leuk Lymph 2011; 52: 59-68.
14. Jukema JW, van Boven AJ, Groenemeijer B, et al. The Asp9 Asn mutation in the lipoprotein lipase gene is associated with increased progression of coronary atherosclerosis. Circulation 1996; 94: 1913-8.
15. Taylor KD, Scheuner M, Rotter J, Yang H. Genetic test to determine non-responsiveness to statin treatment. EP1408121B1, 2011.
16. Butler J, Devane J, Stark P. Pharmaceutical formulations for carrier- mediated transport statins and uses thereof. EP2319501A1, 2011.
17. Vitols S, Norgren S, Juliusson G, Tatidis L, Luthman H. Multilevel regulation of low-density lipoprotein receptor and 3-hydroxy-3- methylglutaryl coenzyme A reductase gene expression in normal and leukemic cells. Blood 1994; 84: 2689-98.
18. Clendening JW, Penn LZ. Targeting tumor cell metabolism with statins. Oncogene 2012; Feb 6. doi: 10.1038/onc.2012.6.[Epub ahead of print]
19. Penn L, Schimmer A, Pandyra A. Treating cancer with statins and compounds having dipyridamole activity. WO2011085473A1, 2011.
20. van der Weide K, de Jonge-Peeters SDPWM, Kuipers F, deVries EGE, Vellenga E. Combining simvastatinwith the farnesyltransferase inhibitor tipifarnib results in an enhanced cytotoxic effect in a subset of primary CD34+ acute myeloid leukemia samples. Clin Cancer Res 2009; 15: 3076-83.
21. Dimitroulakos J, Ye LY, Benzaquen M, Moore MJ, et al. Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications. Clin Cancer Res 2001; 7: 158-67.
22. Kornblau SM, Banker DE, Stirewalt D, et al. Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study. Blood 2007; 109: 2999-3006.
23. Tomiyama N, Matzno S, Kitada C, Nishiguchi E, Okamura N, Matsuyama K. The possibility of simvastatin as a chemotherapeutic agent for all-trans retinoic acid-resistant promyelocytic leukemia. Biol Pharm Bull 2008; 31: 369-74.
24. Sassano A, Lo Iacono M, Antico G, et al. Regulation of leukemic cell differentiation and retinoid-induced gene expression by statins. Mol Cancer Ther 2009; 8: 615-25.
25. O'Brien SG, Meinhardt P, Bond E, et al. Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome P450 3A4 substrate, in patients with chronic myeloid leukaemia. Br J Cancer 2003; 89: 1855-9.
26. Hamadani M, Awan FT, Devine SM. The impact of HMG-CoA reductase inhibition on the incidence and severity of graft-versushost disease in patients with acute leukemia undergoing allogeneic transplantation. Blood 2008; 111: 3091-2.
27. Podhorecka M, Halicka D, Klimek P, Kowal M, Chocholska S, Dmoszynska A. Simvastatin and purine analogs have a synergic effect on apoptosis of chronic lymphocytic leukemia cells. Ann Hematol 2010; 89:1115-24.
28. Winiarska M, Bil J, Wilczek E, et al. Statins Impair Antitumor Effects of Rituximab by Inducing Conformational Changes of CD20. PLoS Medicine. Available at: http://www.plosmedicine.org 2008{pipe}Volume5{pipe}Issue3{pipe}e64 (Accesed on Jan 20, 2012).
29. Shaughnessy J, Barlogie B, Zhan F. Diagnosis, Prognosis and identification of potential therapeutic targets of multiple myeloma based on gene expression profiling. WO2011043809A2, 2011.
30. Shaughnessy J, Barlogie B, Zhan F. Gene expression profiling based identification of CKS1B as a potential therapeutic target in multiple myeloma. US7935679, 2011.
31. Penn LZ, Cledening JW, Boutros PC. Methods and compositions for diagnosing and treating patients having multiple myeloma that respond to statin therapy. WO2011094847A1, 2011.
32. Cohen JI. HMG CoA reductase inhibitors (statins) to treat Epstein- Barr virus-driven lymphoma. Br J Cancer 2005; 92: 1593-8.
33. Ohkawara H, Ishibashi T, Saitoh S, et al. Preventive effects of pravastatin on thrombintriggered vascular responses via Akt/eNOS and RhoA/Rac1 pathways in vivo. Cardiovasc Res 2010; 88: 492-501.
34. Undas A, Topór-Madry R, Tracz W. Simvastatin increases clot permeability and susceptibility to lysis in patients with LDL cholesterol below 3.4 mmol/l. Pol Arch Med Wewn 2009; 119: 354-9.
35. Serebruany, Victor L. Treating Vascular Events with Statins by Inhibiting PAR-1 and PAR-4. US20110160236A1, 2011.
36. Wang L, Rockwood J, Zak D, Devaraj S, Jialal I. Simvastatin reduces circulating plasminogen activator inhibitor 1 activity in volunteers with the metabolic syndrome. Metab Syndr Relat Disord 2008; 6:149-52.
37. Golomb BA, Evans MA. Statin Adverse Effects: A Review of the Literature and Evidence for a Mitochondrial Mechanism. Am J Cardiovasc Drugs 2008; 8: 373-418.
38. Arca M, Pigna G. Treating statin-intolerant patients. Diabetes Metab Syndr Obes 2011; 4: 155-66.
39. Sukhatme VP, Lecker SH, Hanai J. Methods and compositions for the treatment and diagnosis of statin induced myopathy. US20100310574A1, 2010.